Back to trial detailsIntake questionnaire
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Applying to Massachusetts General Hospital Cancer Center · Boston, Massachusetts
Answer a few short questions to share with the research team.
0 of 5 answered